DuoHexaBody-CD37 ® , a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies.

MLA

Oostindie, Simone C., et al. “DuoHexaBody-CD37 ® , a Novel Biparatopic CD37 Antibody with Enhanced Fc-Mediated Hexamerization as a Potential Therapy for B-Cell Malignancies.” Blood Cancer Journal, vol. 10, no. 3, Apr. 2020, p. 30. EBSCOhost, https://doi.org/10.1038/s41408-020-0292-7.

APA

Oostindie, S. C., van der Horst, H. J., Kil, L. P., Strumane, K., Overdijk, M. B., van den Brink, E. N., van den Brakel, J. H. N., Rademaker, H. J., van Kessel, B., van den Noort, J., Chamuleau, M. E. D., Mutis, T., Lindorfer, M. A., Taylor, R. P., Schuurman, J., Parren, P. W. H. I., Beurskens, F. J., & Breij, E. C. W. (2020). DuoHexaBody-CD37 ® , a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies. Blood Cancer Journal, 10(3), 30. https://doi.org/10.1038/s41408-020-0292-7

Chicago

Oostindie, Simone C, Hilma J van der Horst, Laurens P Kil, Kristin Strumane, Marije B Overdijk, Edward N van den Brink, Jeroen H N van den Brakel, et al. 2020. “DuoHexaBody-CD37 ® , a Novel Biparatopic CD37 Antibody with Enhanced Fc-Mediated Hexamerization as a Potential Therapy for B-Cell Malignancies.” Blood Cancer Journal 10 (3): 30. doi:10.1038/s41408-020-0292-7.